In line with trial results, real-world data suggest GLP-1 receptor agonists have certain benefits in patients with moderate to severe chronic kidney disease (CKD).

As earlier outlined, short-term studies in animals and humans have shown GLP-1 to have some direct vasorelaxation action ... in patients receiving GLP1-RA therapy. There are no published studies ...

HealthDay News — The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, ...

Truveta’s groundbreaking study analyzing real-world use of GLP-1 receptor agonist (GLP-1 RA) therapies in adults with overweight or obesity has published in JAMA Network Open, offering critical ...

Even as real-world experiences indicate that microdosing or off-label use of GLP-1 drugs can offer benefits, physicians recommend caution around the dosage, timing, and mechanisms of action for now.

The risks for disease progression and death were lower for patients with stage 3b or higher CKD receiving GLP-1 ... RA on kidney function in patients with moderate to advanced CKD, although ...

The numbers of patients diagnosed with thyroid cancer were 0.17% in the GLP-1 RA group, 0.23% in the DPP4i group, 0.17% in the SGLT2i group, and 0.20% in the sulfonylurea group. (HealthDay News ...

Jan. 31, 2025 (GLOBE NEWSWIRE) -- Truveta’s groundbreaking study analyzing real-world use of GLP-1 receptor agonist (GLP-1 RA) therapies in adults with overweight or obesity has published in JAMA ...